<?xml version="1.0" ?>
<document id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7">
  <chunk id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c0" text="Association of time-to-treatment with outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients">
    <entity charOffset="50-72" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c0.e0" ontology_id="DOID_11339" text="Pneumocystis pneumonia" type="disease"/>
    <entity charOffset="63-72" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c0.e1" ontology_id="DOID_552" text="pneumonia" type="disease"/>
    <entity charOffset="78-97" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c0.e2" ontology_id="DOID_11162" text="respiratory failure" type="disease"/>
  </chunk>
  <chunk id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1" text="Background: The prevalence of pneumocystis pneumonia (PCP) and associated hypoxic respiratory failure is increasing in human immunodeficiency virus (HIV)-negative patients. However, no prior studies have evaluated the effect of early anti-PCP treatment on clinical outcomes in HIV-negative patient with severe PCP. Therefore, this study investigated the association between the time to anti-PCP treatment and the clinical outcomes in HIV-negative patients with PCP who presented with hypoxemic respiratory failure. Methods: A retrospective observational study was performed involving 51 HIV-negative patients with PCP who presented in respiratory failure and were admitted to the intensive care unit between October 2005 and July 2018. A logistic regression model was used to adjust for potential confounding factors in the association between the time to anti-PCP treatment and in-hospital mortality.">
    <entity charOffset="30-52" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e0" ontology_id="DOID_11339" text="pneumocystis pneumonia" type="disease"/>
    <entity charOffset="43-52" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e1" ontology_id="DOID_552" text="pneumonia" type="disease"/>
    <entity charOffset="54-57" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" ontology_id="CHEBI_17642" text="PCP" type="chemical"/>
    <entity charOffset="82-101" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e3" ontology_id="DOID_11162" text="respiratory failure" type="disease"/>
    <entity charOffset="310-313" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" ontology_id="CHEBI_17642" text="PCP" type="chemical"/>
    <entity charOffset="461-464" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" ontology_id="CHEBI_17642" text="PCP" type="chemical"/>
    <entity charOffset="494-513" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e6" ontology_id="DOID_11162" text="respiratory failure" type="disease"/>
    <entity charOffset="614-617" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" ontology_id="CHEBI_17642" text="PCP" type="chemical"/>
    <entity charOffset="635-654" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e8" ontology_id="DOID_11162" text="respiratory failure" type="disease"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e0" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p0" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e0" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p1" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e0" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p2" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e0" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p3" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e1" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p4" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e1" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p5" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e1" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p6" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e1" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p7" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e3" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p8" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e6" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p9" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e2" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e8" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p10" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e3" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p11" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e3" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p12" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e3" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p13" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e6" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p14" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e4" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e8" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p15" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e6" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p16" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e5" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e8" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p17" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e6" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p18" relation="true"/>
    <pair e1="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e7" e2="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.e8" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c1.p19" relation="true"/>
  </chunk>
  <chunk id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c2" text="Results: All patients were treated with appropriate anti-PCP treatment, primarily involving trimethoprim/ sulfamethoxazole. The median time to anti-PCP treatment was 58.0 (28.0-97.8) hours. Thirty-one (60.8%) patients were treated empirically prior to confirmation of the microbiological diagnosis. However, the hospital mortality rates were not associated with increasing quartiles of time until anti-PCP treatment (P = 0.818, test for trend). In addition, hospital mortality of patients received early empiric treatment was not better than those of patients received definitive treatment after microbiologic diagnosis (48.4% vs. 40.0%, P = 0.765). In a multiple logistic regression model, the time to anti-PCP treatment was not associated with increased mortality. However, age (adjusted OR 1.07, 95% CI 1.01-1.14) and failure to initial treatment (adjusted OR 13.03, 95% CI 2.34-72.65) were independently associated with increased mortality."/>
  <chunk id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c3" text="Conclusions: There was no association between the time to anti-PCP treatment and treatment outcomes in HIVnegative patients with PCP who presented in hypoxemic respiratory failure.">
    <entity charOffset="129-132" id="5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7.c3.e0" ontology_id="CHEBI_17642" text="PCP" type="chemical"/>
  </chunk>
</document>
